Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Year-over-year book value per share growth
Latest
5.75%
↓ 35% vs avg
Percentile
P78
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
8.81%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 5.75% |
| Q3 2025 | -18.21% |
| Q2 2025 | 62.75% |
| Q1 2025 | -7.31% |
| Q4 2024 | 4.01% |
| Q3 2024 | -5.80% |
| Q2 2024 | -16.06% |
| Q1 2024 | 26.38% |
| Q4 2023 | -6.27% |
| Q3 2023 | -6.34% |
| Q2 2023 | -56.73% |
| Q1 2023 | 234.64% |
| Q4 2022 | -194.09% |
| Q3 2022 | 33.06% |
| Q2 2022 | -15.26% |
| Q1 2022 | -32.24% |
| Q4 2021 | 1.86% |
| Q3 2021 | 8.83% |
| Q2 2021 | -14.74% |
| Q1 2021 | -10.61% |
| Q4 2020 | -11.85% |
| Q3 2020 | -11.69% |
| Q2 2020 | -2.60% |
| Q1 2020 | 279.24% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |